德国默克公司：Pimicotinib 显示出同类最佳潜力，在腱鞘巨细胞瘤患者中展现显著疗效和重大临床意义的改善

Pimicotinib治疗腱鞘巨细胞瘤（TGCT）的全球临床III期MANEUVER研究达到了主要终点：第25周时客观缓解率（ORR）为54.0%，而安慰剂组仅为3.2%（p<0.0001）。

MANEUVER研究在疼痛、僵硬、关节活动度、身体功能和肿瘤体积减少这五项关键次要终点上均取得显著的统计学和重大临床意义的改善。

该治疗耐受性良好，患者治疗中断和剂量调整的发生率低。

研究结果将于2025年6月1日，在美国临床肿瘤学会（ASCO）年会中以口头报告形式发布。

$和誉-B(02256)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

cornpop
06-02
cornpop
发行价在向你招手$$$

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":440160329159040,"tweetId":"440160329159040","gmtCreate":1748499926611,"gmtModify":1748499931647,"author":{"id":4143269081778110,"idStr":"4143269081778110","authorId":4143269081778110,"authorIdStr":"4143269081778110","name":"和誉医药","avatar":"https://static.tigerbbs.com/adb09e4e1f90e3f4deff5b93da1d691a","vip":5,"userType":5,"introduction":"和誉-B（2256.HK）专注于肿瘤创新药物研发，致力于改善中国及全球病人的生活质量。 ","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1621,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/e43b197d89cdfd888487a956b8cbd537","width":"1789","height":"902"}],"coverImages":[{"img":"https://static.tigerbbs.com/e43b197d89cdfd888487a956b8cbd537","width":"1789","height":"902"}],"title":"德国默克公司：Pimicotinib 显示出同类最佳潜力，在腱鞘巨细胞瘤患者中展现显著疗效和重大临床意义的改善","html":"<html><head></head><body><a href=\"https://laohu8.com/S/02256\">$和誉-B(02256)$</a>\n<img src=\"https://static.tigerbbs.com/e43b197d89cdfd888487a956b8cbd537\" tg-width=\"1789\" tg-height=\"902\">\nPimicotinib治疗腱鞘巨细胞瘤（TGCT）的全球临床III期MANEUVER研究达到了主要终点：第25周时客观缓解率（ORR）为54.0%，而安慰剂组仅为3.2%（p&lt;0.0001）。\nMANEUVER研究在疼痛、僵硬、关节活动度、身体功能和肿瘤体积减少这五项关键次要终点上均取得显著的统计学和重大临床意义的改善。\n该治疗耐受性良好，患者治疗中断和剂量调整的发生率低。\n研究结果将于2025年6月1日，在美国临床肿瘤学会（ASCO）年会中以口头报告形式发布。\n<a href=\"https://laohu8.com/S/02256\">$和誉-B(02256)$</a></body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/02256\">$和誉-B(02256)$</a>\n<img src=\"https://static.tigerbbs.com/e43b197d89cdfd888487a956b8cbd537\" tg-width=\"1789\" tg-height=\"902\">\nPimicotinib治疗腱鞘巨细胞瘤（TGCT）的全球临床III期MANEUVER研究达到了主要终点：第25周时客观缓解率（ORR）为54.0%，而安慰剂组仅为3.2%（p&lt;0.0001）。\nMANEUVER研究在疼痛、僵硬、关节活动度、身体功能和肿瘤体积减少这五项关键次要终点上均取得显著的统计学和重大临床意义的改善。\n该治疗耐受性良好，患者治疗中断和剂量调整的发生率低。\n研究结果将于2025年6月1日，在美国临床肿瘤学会（ASCO）年会中以口头报告形式发布。\n<a href=\"https://laohu8.com/S/02256\">$和誉-B(02256)$</a></body></html>","text":"$和誉-B(02256)$ Pimicotinib治疗腱鞘巨细胞瘤（TGCT）的全球临床III期MANEUVER研究达到了主要终点：第25周时客观缓解率（ORR）为54.0%，而安慰剂组仅为3.2%（p<0.0001）。 MANEUVER研究在疼痛、僵硬、关节活动度、身体功能和肿瘤体积减少这五项关键次要终点上均取得显著的统计学和重大临床意义的改善。 该治疗耐受性良好，患者治疗中断和剂量调整的发生率低。 研究结果将于2025年6月1日，在美国临床肿瘤学会（ASCO）年会中以口头报告形式发布。 $和誉-B(02256)$","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/440160329159040","repostId":0,"isVote":1,"tweetType":1,"viewCount":52649,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02256"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":405,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":441586666726264,"commentId":"441586666726264","gmtCreate":1748847938057,"gmtModify":1748847941963,"authorId":3447477120405680,"author":{"id":3447477120405680,"idStr":"3447477120405680","authorId":3447477120405680,"name":"cornpop","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.27%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":9,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":440160329159040,"objectIdStr":"440160329159040","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"发行价在向你招手$$$","text":"发行价在向你招手$$$","html":"发行价在向你招手$$$","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/440160329159040"}